Genetics Institute, Inc.

Other

Follea International

Applied Biology, Inc.

Rejoy

Jupiter Wellness, Inc.

Suzhou Kintor Pharmaceuticals, Inc.

Global Life Science Partners Limited

John R McCoy

Ofer A Goren

Edward R LaVallie

Neil M Wolfman

Andy Ofer Goren

Elizabeth DiBlasio-Smith

Kathleen Grant

Gordon G Wong

Steven C Clark

Paul F Schendel

Kathleen N Tomkinson

Jack M McLaughlin

Philip Y Tam

Daniel Hafid

Deborah Elliott

Monique Davies

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR&#x2212;NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

Minoxidil adjuvant therapies

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR&#x2014;NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH.

Systems, methods, and kits for treating, preventing, and diagnosing viral infection using an androgen mediated pathway are described. Additionally, methods and kits for guiding treatment of viral respiratory disease are described by a method for testing for polymorphisms in the androgen receptor gene. Further, systems and methods for treatment of viral respiratory disease with various anti-androgens is detailed. Finally, systems, methods, and kits for treating, preventing, and diagnosing SARS-CoV-2 (COVID-19) are presented.

Systems, methods, and kits for diagnostics and treatment of viral respiratory infection

The present invention discloses compositions, methods, and systems of treating female sexual dysfunction by stimulating the contraction of the smooth muscle of the nipple. The smooth muscle in the nipple expresses trace amine associated receptors and thus can be contracted through a class of trace amine associated receptor agonists such as octopamine or tyramine, but any agent that promotes contraction of smooth muscle can be considered for the methods and compositions described herein. The contraction of the smooth muscle erects the nipple and increases female sexual arousal. The smooth muscle stimulatory compound can be formulated in a solution, foam, ointment, gel, spray, lotion, powder, topical cream, emulsion, slow release capsule or any similar method, compound, or delivery vehicle including a pre-wetted gauze or cotton pad. Additionally, the disclosed composition can be used to improve the quality of a sexual experience, e.g., it can increase orgasm intensity or a subject's interest in sex, of females that do not suffer from sexual dysfunction.

TARR receptor agonists for sexual dysfunction

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-&#x3b2; inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-&#x3b2; inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

Disclosed herein are compositions of synephrine and a penetration enhancer and methods of reducing hair loss from pulling by applying the compositions. In one embodiment, the composition is a prewash composition comprising water, synephrine, and PEG-6 caprylic/capric glycerides.

Synephrine compositions

Methods, processes, systems, and apparatuses are disclosed for predicting minoxidil response in the treatment of androgenetic alopecia based on colorimetric assay for sulfotransferase activity. In particular, SULT1A1 activity may be used as an indicator of minoxidil response. A genetic test for alleles of the SULT1A1 gene may be performed to provide a more personalized therapy.

Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia

Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using topical application of a therapeutic agent such as an alpha-1 adrenergic receptor agonist to the nipple-areola complex are disclosed.

Treatment of sexual dysfunction

Traction alopecia and other disorders related to mechanical pulling on hair are treated or prevented by administering a topical composition comprising an alpha-1 adrenergic receptor agonist or another compound or electrical stimulation to contract the arrector pili muscle.

System and method for preventing alopecia

Methods are disclosed for administering electromagnetic radiation (EMR), which may include filtering EMR from part of the EMR spectrum while allowing passage of EMR at a desired wavelength range. Uses may include the treatment of such conditions as psoriasis, vitiligo, pruritus, acne, vitamin-D deficiency and atopic dermatitis. Topical creams, sprays, or other compositions may be used, with or without dosimeters, or in conjunction with an application, which calculates local UV exposure and other factors relating to dosage.

Methods and compositions for administering a specific wavelength phototherapy

Apparatuses are disclosed for performing calorimetric assays with plucked human hair using a device adapted for that purpose. This device may include a transparent reaction vessel connected via a capillary tube to a burst pack, and connected via another capillary tube to a funnel, into which a plucked human hair may be placed.

Devices for performing colorimetric assay with plucked human hair

Methods, processes, systems, and apparatuses are disclosed for predicting anti-androgen therapy response in the treatment of androgenetic alopecia based on a fluorometric assay and proteomics.

Systems and methods for predicting response to anti-androgen therapy for the treatment of androgenetic alopecia

Internally colored glass and glass-like blocks () and the method for making them. No means for coating the internal cavities () of clear glass and glass-like hollow blocks has been available. Color coating provides aesthetically pleasing structures. Internally colored glass and glass-like blocks may be used in building internal room dividers, providing colorful building designs and for providing color relief in heretofore otherwise drab structures.

Internally colored block and process

IL-6 is produced via recombinant DNA techniques. The peptide is useful in the treatment of disorders characterized by deficiencies in hematopoietic cells and in combination with other hematopoietins in cancer therapies.

Growing community of inventors

Carson, CA, United States of America

John R McCoy